DiaGenic seeks microarray partners for breast cancer blood test
This article was originally published in Clinica
Executive Summary
Molecular diagnostic company DiaGenic is looking for technological partners for what it says is a novel means of detecting breast cancer from blood samples. The Oslo, Norway firm said its gene-expression testing method could also be applied to other cancers and Alzheimer's disease, for which there is currently no biologic diagnostic.